The earnings call reflects a strong quarter for TG Therapeutics, marked by significant revenue growth, successful product adoption, and strategic pipeline advancements. However, increased operating expenses and potential market challenges are areas of concern.

Company Guidance

During TG Therapeutics' second quarter 2025 earnings call, the company reported impressive financial and operational performance, primarily driven by the success of its flagship product, BRIUMVI. U.S. net sales for BRIUMVI in Q2 reached approximately $139 million, contributing to total revenue of $141.1 million, which marks a 91% year-over-year increase and a 16% growth from Q1 2025. The company highlighted that nearly 1 in 3 new IV anti-CD20 patients are now prescribed BRIUMVI, and they raised full-year 2025 U.S. net revenue guidance to $575 million. They also outlined strategic efforts to expand BRIUMVI's market reach through the development of a subcutaneous version, aiming to capture 35%-40% of the anti-CD20 market that prefers self-administered options. TG Therapeutics anticipates filing a Biologics License Application (BLA) for subcu BRIUMVI in 2027 and launching in 2028. The company reported GAAP net income of $28.2 million for the quarter, with operating expenses projected to be around $300 million for the full year.

Strong Revenue Growth

Total revenue for Q2 2025 was $141.1 million, including U.S. net product revenue of $138.8 million, representing a 91% increase compared to the same period last year and a 16% growth over the first quarter of this year.

Successful BRIUMVI Adoption

BRIUMVI is now prescribed to nearly 1 in every 3 new IV anti-CD20 patients, with significant growth in patient enrollments and new prescriber accounts.

Commercial Milestones

The company achieved the highest number of new patient enrollments since launch and launched a national television campaign to increase brand awareness.

Pipeline Progress

TG Therapeutics initiated a pivotal Phase III trial for subcutaneous BRIUMVI and dosed the first patient with progressive MS using azer-cel, an investigational CD19-directed CAR-T therapy.

TG Therapeutics (TGTX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

TGTX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 30, 2025	2025 (Q3)	0.22 / -	0.02	―	―	―
Aug 04, 2025	2025 (Q2)	0.21 / 0.17	0.04	325.00% (+0.13)	―
May 05, 2025	2025 (Q1)	0.17 / 0.03	-0.07	142.86% (+0.10)	―
Mar 03, 2025	2024 (Q4)	0.16 / 0.15	-0.09	266.67% (+0.24)	―
Nov 04, 2024	2024 (Q3)	0.03 / 0.02	0.73	-97.26% (-0.71)	―
Aug 06, 2024	2024 (Q2)	-0.05 / 0.04	-0.34	111.76% (+0.38)	―
May 01, 2024	2024 (Q1)	-0.06 / -0.07	-0.28	75.00% (+0.21)	―
Feb 28, 2024	2023 (Q4)	-0.10 / -0.09	-0.39	76.92% (+0.30)	―
Nov 01, 2023	2023 (Q3)	0.06 / 0.73	-0.26	380.77% (+0.99)	―
Aug 01, 2023	2023 (Q2)	-0.25 / -0.34	-0.3	-13.33% (-0.04)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

TGTX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 04, 2025	$35.02	$28.72	-17.99%
May 05, 2025	$43.44	$37.68	-13.26%
Mar 03, 2025	$30.09	$34.42	+14.39%
Nov 04, 2024	$26.90	$24.36	-9.44%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does TG Therapeutics (TGTX) report earnings?

TG Therapeutics (TGTX) is schdueled to report earning on Oct 30, 2025, TBA (Confirmed).

What is TG Therapeutics (TGTX) earnings time?

TG Therapeutics (TGTX) earnings time is at Oct 30, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is TGTX EPS forecast?

TGTX EPS forecast for the fiscal quarter 2025 (Q3) is 0.22.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing